Deutsche Bank AG Sells 255,952 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Deutsche Bank AG trimmed its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 20.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 989,661 shares of the company's stock after selling 255,952 shares during the period. Deutsche Bank AG owned approximately 0.33% of Stevanato Group worth $21,565,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. M&T Bank Corp acquired a new position in Stevanato Group during the fourth quarter worth $572,000. Mutual of America Capital Management LLC bought a new stake in shares of Stevanato Group in the 4th quarter worth $13,848,000. Advantage Alpha Capital Partners LP lifted its position in shares of Stevanato Group by 27.3% during the fourth quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company's stock valued at $6,403,000 after purchasing an additional 63,041 shares in the last quarter. Allianz SE bought a new position in shares of Stevanato Group during the 4th quarter worth approximately $748,000. Finally, Zions Bancorporation N.A. increased its position in shares of Stevanato Group by 29.7% during the fourth quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company's stock valued at $1,482,000 after acquiring an additional 15,555 shares during the last quarter.

Stevanato Group Price Performance

NYSE:STVN traded down €0.23 ($0.26) during trading hours on Tuesday, hitting €24.55 ($27.58). 81,527 shares of the company's stock traded hands, compared to its average volume of 345,172. The firm has a market cap of $7.43 billion, a P/E ratio of 52.23, a P/E/G ratio of 7.18 and a beta of 0.51. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The business's fifty day simple moving average is €21.50 and its two-hundred day simple moving average is €21.23. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.61) and a 52 week high of €25.75 ($28.93).

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. On average, research analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be given a dividend of $0.0613 per share. The ex-dividend date of this dividend is Thursday, June 5th. This represents a yield of 0.3%. This is a boost from Stevanato Group's previous annual dividend of $0.05. Stevanato Group's dividend payout ratio is presently 11.76%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. William Blair reiterated an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. UBS Group decreased their target price on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. Finally, Stephens raised Stevanato Group to a "strong-buy" rating in a research report on Monday, April 21st. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of €25.70 ($28.88).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.